

Financial Tear Sheet

Corporate Profile

Investors

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, immuno-oncology agent Plinabulin, is currently in multiple global registration studies, for the prevention of chemotherapy-induced neutropenia and as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company also has a robust internal early-stage pipeline, and a research collaboration with Fred Hutchinson Cancer Research Center and University of Washington exploring the ubiquitin ligase protein to target and promote the destruction of disease causing proteins, such as oncogenes.

Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, and a unique, highly scalable business model that integrates clinical resources in the U.S. and China, BeyondSpring believes that it is well positioned for expeditious progress towards regulatory approvals and commercialization in a cost-efficient manner.

Primary IR Contact

Laura Perry / Joe Rayne

Argot Partners

Phone: 212.600.1902

E-mail:

BeyondSpring@argotpartners.com

Stock Information

BYSI (Common Stock)

Exchange NASDAQ CM (US Dollar)

Price **\$18.85**

Change (%) ▼ 0.45 (2.33%)

Volume 2,078


52 Week Low \$16.15

Market Cap \$436,844,923

Rolling EPS -2.54

PE Ratio 0

Shares Outstanding 23,174,797



Recent Press Releases & Upcoming Events

December 27, 2018

[BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin](#)

December 21, 2018

[United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring's Lead Asset Plinabulin with Protection to 2036](#)

December 6, 2018

[BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
October 23, 2018	<u>6-K</u>
October 23, 2018	<u>6-K</u>
August 1, 2018	<u>6-K</u>
June 21, 2018	<u>6-K</u>

Corporate Governance

<u>Lan Huang, Ph.D.</u>	Co-founder, Chairman & CEO
<u>Ramon Mohanlal, M.D., Ph.D.</u>	Chief Medical Officer
<u>Edward Dongheng Liu</u>	Chief Financial Officer
<u>G. Kenneth Lloyd, Ph.D.</u>	Chief Scientific Officer
<u>Gordon L. Schooley, Ph.D.</u>	Chief Regulatory Officer